The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OCUL | +19.9% | -53.64% | -14.24% | -32% |
| S&P | +13.95% | +78.35% | +12.25% | +250% |
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.25M | -22.4% |
| Gross Profit | $11.66M | -26.5% |
| Gross Margin | 87.97% | -4.8% |
| Market Cap | $2.59B | 92.6% |
| Market Cap / Employee | $7.96M | 0.0% |
| Employees | 325 | 18.6% |
| Net Income | -$64,654.00K | -33.6% |
| EBITDA | -$68,513.00K | -38.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $737.06M | 88.0% |
| Accounts Receivable | $30.65M | -5.4% |
| Inventory | 3.6 | 17.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $74.15M | 0.4% |
| Short Term Debt | $2.82M | 45.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.91% | 12.6% |
| Return On Invested Capital | -59.60% | 21.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$57,088.00K | -44.0% |
| Operating Free Cash Flow | -$54,249.00K | -37.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.67 | 5.56 | 6.61 | 8.22 | 116.42% |
| Price to Sales | 20.82 | 28.27 | 38.54 | 52.09 | 131.34% |
| Price to Tangible Book Value | 3.67 | 5.56 | 6.61 | 8.22 | 116.42% |
| Enterprise Value to EBITDA | -15.38 | -19.33 | -27.83 | -29.87 | 32.50% |
| Return on Equity | -57.2% | -63.4% | -81.8% | -54.9% | -42.39% |
| Total Debt | $76.22M | $76.94M | $77.01M | $76.97M | 1.56% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
